Curetis and OpGen Close Business Combination - Seite 2

Dr. Werner Schaefer, Dr. Rudy Dekeyser, and Dr. Nils Clausnitzer will continue to serve on the Company’s supervisory board until the liquidation of the Company has been completed and Curetis N.V. ceases to exist.

The new OpGen board of directors will initially include non-executive directors William E. Rhodes III as chairman, Evan Jones, Don Elsey, Mario Crovetto, Prabhavathi Fernandes and the new President and CEO of OpGen, Oliver Schacht. The executive officers of OpGen in addition to CEO Oliver Schacht will be Tim Dec continuing to serve as CFO and managing the finance and G&A teams globally and Johannes Bacher, one of the Curetis founders, as COO who will be running global R&D and operations.

Curetis USA Inc. will be dissolved in the coming weeks and its employees will be joining OpGen. The US commercial team going forward includes Chief Commercial Officer for the Americas Chris Emery and Chief Marketing and Scientific Affairs Officer Faranak Atrzadeh.

Oliver Schacht, PhD and Johannes Bacher will retain their roles as managing directors of Curetis GmbH while Dr. Achim Plum resigned from his role as managing director of Curetis GmbH effective today to pursue other opportunities. However, Dr. Plum remains a managing director of Ares Genetics GmbH and will continue to support the newly formed OpGen group as a consultant.

Dr. Andreas Posch will continue to serve as managing director and CEO of Ares Genetics GmbH and in addition will also serve on the expanded OpGen executive team bringing AI-powered and NGS-based capabilities into the combined business.

OpGen and the Company had entered into a definitive agreement to combine their businesses on September 4, 2019. H.C. Wainwright & Co. acted as strategic advisor to the Company while Crosstree acted as advisor to OpGen. Ballard Spahr LLP served as legal counsel to OpGen and Linklaters LLP as legal counsel to Curetis.

###

About Curetis

Curetis GmbH’s goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.

Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.